4.7 Article

Significance of FEV3/FEV6 in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD Analysis of the SPIROMICS Cohort

Journal

CHEST
Volume 161, Issue 4, Pages 949-959

Publisher

ELSEVIER
DOI: 10.1016/j.chest.2021.10.046

Keywords

COPD; early airflow obstruction; small airways disease; spirometry; FEV3; FEV6; FEV3/FEV6

Funding

  1. National Institutes of Health (NIH) /National Heart, Lung, and Blood Institute [HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C, U01 HL137880, U24 HL141762]
  2. Foundation for the National Institutes of Health
  3. COPD Foundation from AstraZeneca/MedImmune
  4. Bayer
  5. Bellerophon Therapeutics
  6. Boehringer Ingelheim Pharmaceuticals, Inc.
  7. Chiesi Farmaceutici S.p.A.
  8. Forest Research Institute, Inc.
  9. GlaxoSmithKline
  10. Grifols Therapeutics, Inc.
  11. Ikaria, Inc.
  12. Takeda Pharmaceutical Company
  13. Novartis Pharmaceuticals Corporation
  14. Theravance Biopharma
  15. Nycomed GmbH
  16. Viatris
  17. ProterixBio
  18. Regeneron Pharmaceuticals, Inc.
  19. Sanofi
  20. Sunovion

Ask authors/readers for more resources

The study found that FEV3/FEV6 below the lower limit of normal is associated with the development and worsening of various respiratory-related diseases, including COPD. This spirometric index can be used to identify early airflow abnormalities and has important implications for patient evaluation and prediction.
BACKGROUND: Small airways are known to be affected early in the course of COPD; however, traditional spirometric indices may not accurately identify small airways disease. RESEARCH QUESTION: Can forced expiratory volume in 3 s/forced expiratory volume in 6 s (FEV3/FEV6) identify early airflow abnormalities and predict future clinically important respiratory-related outcomes, including development of COPD? STUDY DESIGN AND METHODS: The study included 832 current and former smokers with postbronchodilator FEV1/FVC >= 0.7 from the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) cohort. Participants were classified as having a reduced pre-bronchodilator FEV3/FEV6 based on lower limit of normal (LLN) values. Repeatability analysis was performed for FEV3 and FEV6. Regression modeling was used to evaluate the relationship between baseline FEV3/FEV6 and outcome measures, including functional small airways disease, on thoracic imaging and respiratory exacerbations. Interval censored analysis was used to assess progression to COPD. RESULTS: FEV3/FEV6 less than the LLN at baseline, defined as reduced compared with FEV3/FEV6 at or above the LLN, was associated with lower FEV1, poorer health status (St. George's Respiratory Questionnaire score), more emphysema, and more functional small airways disease on quantitative imaging. FEV3 and FEV6 showed excellent agreement between repeat measurements. A reduced FEV3/FEV6 was associated with increased odds of a severe respiratory exacerbation within the first year of follow-up and decreased time to first exacerbation. A low FEV3/FEV6 was also associated with development of COPD according to spirometry results (post-bronchodilator FEV1/FVC < 0.7) during study follow-up. INTERPRETATION: FEV3/FEV6 is a routinely available and repeatable spirometric index that can be useful in the evaluation of early airflow obstruction in current and former smokers without COPD. A reduced FEV3/FEV6 can identify those at risk for future development of COPD and respiratory exacerbations.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available